Physician profile
Roberto Andrade
NPI 1508946922
$8,546.56
in general payments reported to CMS, 2019-2025
21 companies · $729 in 2025
The $729 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $706 · 2021: $1,035 · 2022: $1,499 · 2023: $1,836 · 2024: $1,445 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,010.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,251.73 | 2019-2025 | Biktarvy |
| Insmed, INC. | $1,127.90 | 2019-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $1,112.40 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $1,070.19 | 2021-2025 | Dalvance, Avycaz |
| Viiv Healthcare Company | $864.37 | 2019-2025 | Dovato, Cabenuva |
| Paratek Pharmaceuticals, INC. | $810.56 | 2019-2025 | Nuzyra |
| Shionogi INC | $515.30 | 2021-2025 | Fetroja |
| Janssen Products, LP | $385.35 | 2019-2021 | |
| Amgen INC. | $258.46 | 2024-2025 | Evenity, Repatha |
| Astellas Pharma US INC | $232.56 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $231.96 | 2023-2025 | Xerava, Zevtera, Xacduro |
| Melinta Therapeutics, LLC | $178.98 | 2021-2023 | Rezzayo, Orbactiv, Kimyrsa |
| Allergan, INC. | $152.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $122.52 | 2024 | Airsupra |
| Tetraphase Pharmaceuticals, INC. | $59.55 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $54.60 | 2021-2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $35.00 | 2021 | |
| Novo Nordisk INC | $24.73 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.07 | 2024 | |
| Lilly USA, LLC | $19.30 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.82 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.